Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000551
• EU PAS number:
  EUPAS1000000551
• Study ID:
  1000000551
• Official title and acronym:
  Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
• DARWIN EU® study:
  No
• Study countries:
  Korea, Republic of

  United States
• Study description:
  This study aims to compare ticagrelor and prasugrel, P2Y12 antiplatelet agents commonly used in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). By conducting a direct, head-to-head comparison, this research will provide valuable insights into their associations with various ischemic and hemorrhagic outcomes. The findings are expected to inform and guide clinical decision-making, helping to optimize treatment strategies for patients with ACS.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Yonsei University

UMass Chan Medical School

Networks

Observational Health Data Sciences and Informatics (OHDSI) Network

Study timelines

Date when funding contract was signed

Planned: 01/03/2025

Actual: 01/03/2025

Study start date

Planned: 14/04/2025

Actual: 14/04/2025

Data analysis start date

Planned: 14/04/2025

Actual: 14/04/2025

Date of final study report

Planned: 31/12/2025

Study protocol

Initial protocol

TicaPra_Research Protocol_20250411.pdf

Github repository (study package & protocol)

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable